Commodore Capital reduced its stake in Centessa Pharmaceuticals (NASDAQ:CNTA) by 1,850,000 shares in the fourth quarter, according to a February 17, 2026, SEC filing. The estimated transaction value, based on quarterly average pricing, was approximately $46.86 million.
According to a filing with the Securities and Exchange Commission dated February 17, 2026, Commodore Capital sold 1,850,000 shares of Centessa Pharmaceuticals in the fourth quarter. The estimated transaction value, calculated using the average closing price for the quarter, was $46.86 million. The fund’s quarter-end position value in Centessa declined by $44.10 million, a change that captures both sale activity and price movement.
-
Commodore Capital reduced its Centessa stake to 1.66% of reportable AUM after this sale.
-
Top holdings after filing:
-
NASDAQ:RLAY: $143.82 million (9.6% of AUM)
-
NASDAQ:ALKS: $99.33 million (6.6% of AUM)
-
NASDAQ:TYRA: $88.73 million (5.9% of AUM)
-
NASDAQ:XENE: $80.68 million (5.4% of AUM)
-
NASDAQ:SYRE: $78.24 million (5.2% of AUM)
-
-
As of February 17, 2026, CNTA shares were priced at $24.94, up 53.4% over the past year, outperforming the S&P 500 by 34.19 percentage points.
|
Metric |
Value |
|---|---|
|
Market capitalization |
$3.35 billion |
|
Revenue (TTM) |
$15.00 million |
|
Net income (TTM) |
($242.70 million) |
|
Price (as of market close 2/17/26) |
$24.94 |
-
Centessa Pharmaceuticals’ pipeline includes late-stage clinical assets such as Lixivaptan for autosomal dominant polycystic kidney disease and SerpinPC for hemophilia, along with early-stage candidates targeting rare diseases and immunological disorders.
-
The company operates a research-driven business model focused on discovering, developing, and advancing novel therapeutics through clinical trials, with the goal of achieving regulatory approvals and future commercialization.
-
Primary customers are expected to be healthcare providers, hospitals, and specialty clinics treating patients with rare diseases, hematological conditions, and autoimmune disorders.
Centessa Pharmaceuticals plc is a clinical-stage biotechnology company headquartered in the United Kingdom, with a focus on advancing a diverse pipeline of innovative medicines targeting rare and serious diseases. The company leverages a portfolio approach, developing multiple assets across different therapeutic areas to diversify risk and maximize clinical impact. Its strategy centers on progressing high-potential candidates through pivotal trials, aiming to address significant unmet medical needs and establish a competitive position in the biopharmaceutical sector.
